TGFB1 and neoplasm: Recently, numerous studies identified that activated TGF beta and EMT-related pathways could restrict the penetration of lymphocyte subpopulations into the tumor parenchyma (59), while targeted small molecule (TGF-β) inhibitor therapy could restore antitumor immunity via remodeling the TME feature (60, 61).